Australia markets closed

Vir Biotechnology, Inc. (VIR)

NasdaqGS - NasdaqGS Delayed price. Currency in USD
Add to watchlist
51.46+1.30 (+2.58%)
As of 11:51AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close50.16
Open50.08
Bid51.38 x 1200
Ask51.49 x 1000
Day's range49.75 - 51.53
52-week range11.65 - 75.00
Volume195,394
Avg. volume1,466,687
Market cap6.5B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-14.64
Earnings date12 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.67
  • GlobeNewswire

    Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2020 Financial Results on August 11, 2020

    SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that it will provide a corporate update and report financial results for the second quarter ended June 30, 2020 on Tuesday, August 11, 2020. The update will be provided via a press release after market close, and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.About Vir BiotechnologyVir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting hepatitis B virus, influenza A, SARS-CoV-2, human immunodeficiency virus and tuberculosis. CONTACT: Contact: Investors Neera Ravindran, M.D. VP, Head of Investor Relations & Strategic Communications nravindran@vir.bio +1-415-506-5256 Media Julie Normart W2O Group jnormart@w2ogroup.com +1-559-974-3245

  • GlobeNewswire

    Vir Biotechnology Announces Pricing of Public Offering of Common Stock

    SAN FRANCISCO, July 07, 2020 -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today.

  • GlobeNewswire

    Vir Biotechnology Announces Proposed Public Offering of Common Stock

    Vir Biotechnology, Inc. (VIR), a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases, today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 6,200,000 shares of its common stock. In addition, Vir expects to grant the underwriters a 30-day option to purchase up to 930,000 additional shares of its common stock offered at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined.